Connect your AI

Kymera Therapeutics KYMR Restricted Cash

Restricted Cash at other companies

IncyteINCY

$1.84M+10.3%

TG TherapeuticsTGTX

$1.35M+3.8%

Merck & Co.MRK

$71M-31.1%

Regeneron PharmaceuticalsREGN

——

ImmunityBio, Inc.IBRX

——

Protagonist TherapeuticsPTGX

——

Other financials

Income statement

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kymera Therapeutics's restricted cash?: Kymera Therapeutics (KYMR) reported restricted cash of $5.81M in Q1 2026.
How has Kymera Therapeutics's restricted cash changed year-over-year?: Kymera Therapeutics's restricted cash increased by 0.1% year-over-year, from $5.81M to $5.81M.
What is the long-term trend for Kymera Therapeutics's restricted cash?: Over 5 years (2020 to 2025), Kymera Therapeutics's restricted cash has grown at a 29.6% compound annual growth rate (CAGR), from $1.59M to $5.8M.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.